Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 16 Mar 2023
Sanofi cuts US list price of Lantus, its most prescribed insulin, by 78% and caps out of pocket Lantus costs at $35 for all patients with commercial insurance
16 March 2023 - Sanofi announces that it will cut the list price of Lantus (insulin glargine injection) 100 units/mL, ...
Posted by Michael Wonder on 16 Mar 2023
ICER publishes white paper on using comparative effectiveness research to address prescription drug spending in California
16 March 2023 - State policy makers and purchasers in California are uniquely positioned to further integrate comparative effectiveness research ...
Posted by Michael Wonder on 16 Mar 2023
FDA approves expanded indication for Telix's Illuccix to include patient selection for PSMA directed radioligand therapy
16 March 2023 - Telix Pharmaceuticals today announces that the US FDA has approved a supplementary new drug application for ...
Posted by Michael Wonder on 16 Mar 2023
Pfizer will have to pay rebates to Medicare for five drugs under Biden plan to lower Rx costs
16 March 2023 - Five of Pfizer’s drugs will cost less for Medicare recipients starting next month as part of President ...
Posted by Michael Wonder on 16 Mar 2023
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP
16 March 2023 - Ipsen today announced that the US FDA PDUFA goal date, for the resubmitted new drug application for ...
Posted by Michael Wonder on 15 Mar 2023
Zanubrutinib in chronic lymphocytic leukaemia: additional benefit for certain patients
15 March 2023 - For adults with relapsed/refractory chronic lymphocytic leukaemia who have not yet received a BTK or BCL2 inhibitor, ...
Posted by Michael Wonder on 15 Mar 2023
HHS releases initial guidance for historic Medicare drug price negotiation program for price applicability year 2026
15 March 2023 - For the first time, Medicare will be able to negotiate prices directly with drug companies, ensuring ...
Posted by Michael Wonder on 15 Mar 2023
Inflation Reduction Act tamps down on prescription drug price increases above inflation
15 March 2023 - HHS announces savings for some people with Medicare on 27 Part B prescription drugs. ...
Posted by Michael Wonder on 15 Mar 2023
ICER publishes white paper recommending health technology assessment methods that support health equity
15 March 2023 - Informed by expert advisory group and input from external stakeholders, white paper highlights on-going need to ...
Posted by Michael Wonder on 15 Mar 2023
FDA authorises bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years of age
14 March 2023 - Today, the US FDA amended the emergency use authorisation of the Pfizer-BioNTech COVID-19 vaccine, bivalent to provide ...
Posted by Michael Wonder on 15 Mar 2023
China National Medical Products Administration accepts regulatory submission for Nucala (mepolizumab) in severe eosinophilic asthma
14 March 2023 - GSK today announced that the China National Medical Products Administration has accepted for review a new drug ...
Posted by Michael Wonder on 15 Mar 2023
argenx announces UK MHRA approval of Vyvgart for the treatment of generalised myasthenia gravis
15 March 2023 - argenx is committed to collaborating with local authorities to facilitate broad and rapid access to Vyvgart for ...
Posted by Michael Wonder on 15 Mar 2023
MHRA to receive £10 million from HM Treasury to fast track patient access to cutting edge medical products
15 March 2023 - A total of £10 million has been awarded to the Medicines and Healthcare products Regulatory Agency to ...
Posted by Michael Wonder on 15 Mar 2023
EMA-FDA parallel scientific advice program has ‘limited’ uptake
14 March 2023 - A review of the last five years of the parallel scientific advice program between the FDA ...
Posted by Michael Wonder on 14 Mar 2023
BMS, Pfizer, AbbVie drugs likely to face US price negotiation
13 March 2023 - The blood thinner Eliquis from BMS, Pfizer's breast cancer drug Ibrance and AbbVie's leukaemia treatment Imbruvica ...